Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

NCT00101907 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated per recommendation of Data Review Team

Conditions

Lung Cancer
Pancreatic Cancer
Esophageal Cancer

Interventions

DRUG: AMG 706
BIOLOGICAL: Panitumumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Amgen